Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Kidney, liver & lung · 2026

Trutakna (atacicept-vymj)

The FDA approved Trutakna (atacicept-vymj) on July 7, 2026 to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.
Brand name
Trutakna
Generic name
atacicept-vymj
FDA approval date
July 7, 2026
Approved use (FDA wording)
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
Company
Vera Therapeutics Inc..
Application
BLA761486
Dosage form / route
INJECTABLE · SUBCUTANEOUS
Boxed warning on label
Not listed
Category on this site
Kidney, liver & lung

Indications and usage, from the FDA label

TRUTAKNA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. TRUTAKNA is a B-lymphocyte stimulator (BLyS)-specific inhibitor and A Proliferation Inducing Ligand (APRIL) blocker indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at ri…

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.